The study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Women of childbearing potential (including those who have had a tubal ligation) must have a documented negative pregnancy test within  days prior to planned initiation of taselisib; women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form on nonhormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for  months after the last dose of study treatment
For women of childbearing potential: abstinent or use an effective form of contraceptive method for at least  months for cobimetinib and at least  months for atezolizumab
For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least  months after the termination visit.
For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least  months after the termination visit.
Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception
Women of childbearing potential and men with partners of childbearing potential, must be willing to use a highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the participants and/or partner, and to continue the use of contraception for the duration of study treatment and for at least  months after the last dose of study treatment
For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective form of hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner, and to continue the use of contraception for the duration of study treatment and for at least  months after the last dose of study treatment.
For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least  months after the termination visit.
For women of childbearing potential (defined as physiologically capable of becoming pregnant), agreement to use of highly effective contraception for at least  year following ACTR infusion. For men with partners of childbearing potential, agreement to use effective barrier contraception for at least  year following ACTR infusion
Patients capable of childbearing are using adequate contraception
Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential
If the patient is of childbearing potential or their partner(s) is of childbearing potential, they must agree to use highly effective method of contraception while on study and for  months after receiving all protocol-related therapy.
Willingness to use contraception if childbearing potential
For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least  months after the termination visit.
Pregnancy or women of childbearing potential not willing/able to use contraception during protocol treatment
Female patients of childbearing potential must use two highly effective forms of contraception
Women of childbearing potential (per University of Wisconsin Carbone Cancer Center [UWCCC] policy definition) must agree to use effective contraception as discussed with treating oncologist for the duration of the study
Women of childbearing potential must use method(s) of contraception; the individual methods of contraception should be determined in consultation with the treating physician or investigator
Pregnant or lactating women; women and men of childbearing age should use effective contraception while on this study and continue for  year after all treatment is finished
Women with childbearing potential and partners must both use effective contraception during the study and for  months after the last dose
Pregnant or lactating women; women and men of childbearing age should use effective contraception while on this study and continue for  year after all treatment is finished
Patients must be willing to use contraception if they have childbearing potential
Pregnancy, or unwillingness to use contraception if they have childbearing potential
Pregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least  months thereafter
Women of childbearing potential must be non-pregnant and non-lactating and willing to use highly effective form of contraception during radiation therapy
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months after completion of treatment
Women of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective, non-hormonal form of contraception (including abstinence) or two effective forms of non-hormonal contraception by the patient and/or partner; contraception must continue for the duration of study treatment and for at least seven () months after the last dose of study treatment
Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further  months after the end of treatment
Patients must be willing to use contraception if they have childbearing potential
Breastfeeding, pregnant, women of childbearing potential not using contraception
The study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Patients of childbearing potential must agree to abstinence or the use of effective contraception
Patients of childbearing potential must agree to use effective contraception until at least  months after treatment with dabrafenib and trametinib
Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least  months thereafter
Patients must be willing to use contraception if they have childbearing potential
Patients must be willing to use contraception if they have childbearing potential
Patients must be willing to use contraception if they have childbearing potential
Patients of childbearing or child-fathering potential must be willing use an effective method of contraception while being treated on this study and for  months after the last cell infusion
Females: Pregnant or breast?feeding women, or women of childbearing potential unless effective method of contraception is used during and for  months after the trial. Males: unless an effective method of contraception is used during and for  months after the trial.
Pregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least  months thereafter
Women of childbearing potential must have a negative pregnancy test and must agree to the use of effective contraception while on treatment; men must also agree to the use of effective contraception while on treatment
Pregnancy or breastfeeding (women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable); radiation therapy is also contraindicated in pregnancy
The study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable); these potential risks may also apply to GSK
Patients who are pregnant or nursing; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; if a patient becomes pregnant while the patient receives trametinib and/or GSK, the potential hazard to the fetus should be explained to the patient
DONOR: Breast feeding or pregnant females; donors of childbearing potential must use an effective method of contraception during the time they are receiving filgrastim
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter, which should be for at least  months after the completion of protocol therapy
Pregnant or lactating; patients of childbearing potential must use an effective method of contraception
For female participants of childbearing potential, agreement to use highly effective form(s) of contraception and to continue its use for  months after the last dose of MOXR
Women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for  months after the last dose of study treatment
Women of childbearing potential and male participants must agree to use an effective method of contraception
Women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Agreement of women of childbearing potential to use highly effective contraception during receipt of study drug and up to  days ( weeks) from the last dose of nivolumab/placebo and men receiving nivolumab/placebo who are sexually active with women of childbearing potential to use highly effective contraception during receipt of study drug for  weeks from the last dose of nivolumab/placebo.
Men and women of childbearing age and potential, who are not willing to use effective contraception
For female participants of childbearing potential, agreement to use highly effective forms of contraception Dose-Escalation Portion of the Study:
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months thereafter
Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months thereafter
Women of childbearing potential not using a medically acceptable means of contraception
Women of childbearing potential must implement adequate contraception in the opinion of the investigator
Women of childbearing potential must use effective contraception
Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months following last treatment
Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for males at least  months thereafter, and for females at least  months thereafter
Women of childbearing potential and male participants with partners of childbearing potential must agree to use a \highly effective\ non-hormonal form of contraception or two \effective\ forms of non-hormonal contraception by the patient and/or partner. Contraception must continue for the duration of study treatment and for at least  months after the last dose of study treatment
Pregnant or breast-feeding women and women of childbearing age or men who are unwilling to use adequate contraception; females of childbearing age and potential (i.e., not surgically sterilized) must use a second form of contraception, including total abstinence, intra-uterine device, double-barrier contraception, or other non-hormonal form of contraception
Patients must be willing to use contraception if they have childbearing potential
Men and women of childbearing potential must be willing to us two highly effective forms of contraception while on treatment and for at least  months after last dose of study drug.
If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for  months after the end of active therapy
Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months after treatment
Women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form on nonhormonal contraception or two effective forms of nonhormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for  months after the last dose of study treatment
Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months thereafter
Women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study
Pregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least  months thereafter
Women of childbearing potential and male participants must use an effective contraception method; (until at least  days following treatment)
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months thereafter
Pregnant or lactating women; women and men of childbearing age should use effective contraception while on this study and continue for  year after all treatment is finished
Women of childbearing potential (WOCBP) should be willing to use  forms of contraception; male patients should be willing to use contraception
Stated willingness to use contraception in women of childbearing potential.
Pregnant or lactating; patients of childbearing potential must use an effective method of contraception
Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least  months thereafter
The study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib/GSK, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Pregnant or nursing women or women of childbearing potential unless using effective contraception as determined by the investigator
Patients must be willing to use contraception if they have childbearing potential
Pregnancy, or unwillingness to use contraception if they are have childbearing potential
Use of effective contraception by women of childbearing potental.
Women of childbearing potential not using a medically acceptable means of contraception for the duration of the study.
Women of childbearing age must be on effective contraception
Men of childbearing potential must consent to use barrier contraception while on treatment and for  days thereafter
For women of childbearing potential, agreement to use two effective forms of contraception
For women of childbearing potential, agreement to use two effective forms of contraception
For women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception
For women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception
Women who are pregnant or breastfeeding, or women of childbearing potential without using dual forms of effective contraception
For men and women of childbearing potential, willingness to abstain from sexual intercourse or employ an effective method of contraception during the study drug administration and follow-up periods
For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least  months after the termination visit.
Women of childbearing potential must be willing to use a highly effective form of contraception for the duration of the trial and for  weeks ( half-lives) after the last dose of treatment
Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least  months thereafter
For women of childbearing potential, agreement to use two effective forms of contraception
Women of childbearing potential (WOCBP) and men must use highly effective methods of contraception
For women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception
Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in the protocol.
Female participants of childbearing potential must use effective contraception as defined by study protocol and cannot be pregnant or breastfeeding. NSCLC-specific Inclusion Criteria:
The study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
For women of childbearing potential, agreement to use two effective forms of contraception
For women of childbearing potential and men with partners of childbearing potential, agreement to use two effective forms of contraception
Participants of childbearing age must use effective contraception
Cohort A: Men and women of childbearing potential must be willing to use effective contraception while on treatment and for at least  months thereafter
For fertile men or women of childbearing potential, documented willingness to use a highly effective means of contraception
Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding
Women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception for  months after study treatment is completed; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least  months after study treatment is completed; if a female patient or a female partner of a patient becomes pregnant while the patient receives talazoparib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
 Females of childbearing potential on denosumab and not willing to continue to use  highly effective method of contraception during treatment and for  months after the end of treatment
Concurrent oral contraceptive use / Women of childbearing potential not using highly effective means of contraception;
Women of childbearing potential must agree to use effective contraceptives (as discussed with their physician) while participating in this study
Women of childbearing potential should use effective contraception during and for two months after stopping fingolimod
Pregnancy or potential pregnancy and nursing; female subjects of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception; contraception must continue for the duration of study treatment
Pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use highly effective method of contraception
The patient, if of childbearing potential, is willing to use effective, non-hormonal contraception while on treatment and for at least  months following the last dose of therapy
Females of childbearing potential should avoid becoming pregnant and use highly effective contraception while on treatment and for at least  month after finishing treatment.
Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy
